The clinical results presented in Los Cabos are very encouraging and mirror the results the patients I treated in my practice in Miami. The MILD™ procedure certainly offers a minimally invasive alternative to open surgery with short recovery and rehabilitation times
San Jose CA (PRWEB) July 16, 2008
Vertos Medical Inc, a privately held medical device manufacturer focusing on minimally invasive treatment of lumbar spinal stenosis (LSS), announced presentation of its clinical results of its proprietary Minimally Invasive Lumbar Decompression, MILD™, procedure. The MILD procedure, is a simple, percutaneous, fluoroscopically guided treatment for central canal Lumbar Spinal Stenosis,(LSS). MILD can be performed under local anesthesia and substantially reduces the tissue damage and tissue removal associated with other minimally invasive or open surgeries. LSS is diagnosed in 1.5 million Americans each year. Vertos has obtained FDA clearance for sale of the MILD devices in the USA.
Clinical results on 32 patients with moderate to severe LSS have shown that all patients were discharged either the same day or the day following the MILD™ procedure. These patients were treated at 11 medical centers of excellence. No complications or adverse events were reported.
Clinical results included a 90% decrease in pain as measured by the Visual Analog Scale (VAS), as well as improved mobility, represented by a decrease in the Oswestry Disability Index (ODI) of 84%. All patients reported had discontinued the use of narcotics or pain medication at 6 weeks following the MILD procedure.
These results were presented at the recently held Spine Technology Education Group's 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos by Jonathan Hyde MD, a leading spine surgeon. Dr Hyde practices at Mount Sinai Medical Center in Miami Beach, Florida.
"The clinical results presented in Los Cabos are very encouraging and mirror the results the patients I treated in my practice in Miami. The MILD™ procedure certainly offers a minimally invasive alternative to open surgery with short recovery and rehabilitation times" said Jonathan Hyde MD. Richard Johnson MD, Vertos President and CEO added "LSS affects 1.5 million Americans each year. The MILD™ procedure will offer many of these patients a minimally invasive alternative to invasive open surgery, with shorter procedure, hospitalization and rehab times. We are very pleased and encouraged by the clinical results Dr. Hyde presented"
For further information, please contact Herbert Mertens via email at hmertens(at)vertosmed.com or via telephone at (619)602-0061.